TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Director/PDMR
Shareholding
Alderley Park, UK - 4 March 2025: TheraCryf plc
(AIM: TCF), the clinical stage drug development company focussing
on oncology and neuropsychiatry has been notified that
Dr Helen Kuhlman, Chief Business Officer has
purchased 1,500,000 Ordinary Shares of 0.25 pence
each ("Ordinary Shares") at a price of 0.24 pence per
Ordinary Share.
The notifiable interest of Dr Helen Kuhlman is
now 2,555,744 Ordinary
Shares, representing 0.5% of the issued Ordinary
Share capital of the Company.
|
Notification
of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
|
|
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
|
a.
|
Name
|
Dr Helen Kuhlman
|
|
2
|
Reason for
notification
|
|
|
a.
|
Position/Status
|
Chief Business Officer (PDMR)
|
|
b.
|
Initial notification/ Amendment
|
Initial
|
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
|
a.
|
Name
|
TheraCryf plc
|
|
b.
|
LEI
|
213800NO3E6TSTQO8K20
|
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial instrument, type
of instrument
Identification Code
|
Ordinary Shares of 0.25p
each
GB00BSVYN304
|
|
b.
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|
c.
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
0.24 pence
|
1,500,000
|
|
|
d.
|
Aggregated information
- Aggregated Volume
- Price
|
As above
|
|
e.
|
Date of the transaction
|
|
|
f.
|
Place of the transaction
|
XLON
|
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44
(0)1625 315 090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD & Joint
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
|
+44 (0)20 7220 0500
|
|
Turner Pope Investments (Joint Broker)
James Pope / Andy
Thacker
|
+44
(0)20 3657 0050
|
|
Vigo Consulting
Rozi Morris
|
+44
(0)20 7390 0231
theracryf@vigoconsulting.com
|
|
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].
The Company's strategy is to
generate compelling data sets to preclinical and/or clinical proof
of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla
SA, in neurodevelopmental disorders. The Company has sourced
know how for programmes from companies such as Shire (now
Takeda).
TheraCryf has worked with and has
ongoing collaborations with major universities and hospitals such
as the University of Manchester, La Sapienza (Università di Roma),
the Erasmus Medical Centre, Rotterdam, Kings College London and the
University of Michigan.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is quoted on AIM
in London and trades under the ticker symbol TCF.
For further information, please
visit: www.theracryf.com.
